Please login to the form below

Not currently logged in
Email:
Password:

Novartis to buy Ebewe Pharma generics unit

Novartis has signed an agreement to purchase Ebewe Pharma's speciality generic injectables business for €925m

Novartis has signed an agreement to purchase Ebewe Pharma's speciality generic injectables business for €925m.

The deal will see Sandoz - Novartis' generic division and the second-largest generics company in the world - expand its generic oncology portfolio considerably.

"The addition of Ebewe Pharma's leading portfolio of oncology medicines fits our strategy and improves our ability to help cancer patients around the world by providing easier access to therapies. These medicines will remain the backbone of multi-drug treatments in the fight against cancer, one of the world's leading causes of death," said Dr Daniel Vasella, chairman and CEO of Novartis. "Ebewe Pharma will further strengthen our pipeline with many planned near-term launches."

Ebewe Pharma, an Austrian company, has built a lot of its success by developing value-added products such as advanced delivery devices and innovative package (eg Onco-Safe), rather than just pure generic versions of branded equivalents.

Sandoz plans to form a new global centre of excellence, based in Austria and led by Friedrich Hillebrand. The business will centre around the company's new acquisition and will aim to capitalise on Ebewe's previous success in hospital marketing and string customer partnerships.

The €925m cash deal, expected to be completed in 2009, will include the production site in Austria along with research, development and manufacturing assets of the business. It does not include Ebewe Pharma's injectable neurological products business. 

21st May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics